IRADIMED Past Earnings Performance
Past criteria checks 5/6
IRADIMED has been growing earnings at an average annual rate of 27.7%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 16.8% per year. IRADIMED's return on equity is 22.3%, and it has net margins of 26.1%.
Key information
27.7%
Earnings growth rate
25.5%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 16.8% |
| Return on equity | 22.3% |
| Net Margin | 26.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Aug 08
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
Feb 23Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
Feb 07Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
Nov 06Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Oct 13At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
Feb 05Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y
Oct 10IRadimed: Record Revenue Could Translate To Share Price Appreciation
Aug 23Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching
Aug 17iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M
Jul 29IRadimed: Reduce Equity Beta With Upside Capture
Jul 18IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively
Jul 13At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?
Feb 05Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital
Jan 12Revenue & Expenses Breakdown
How IRADIMED makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 71 | 19 | 31 | 3 |
| 30 Jun 24 | 69 | 19 | 30 | 3 |
| 31 Mar 24 | 68 | 18 | 28 | 3 |
| 31 Dec 23 | 66 | 17 | 27 | 3 |
| 30 Sep 23 | 63 | 16 | 26 | 3 |
| 30 Jun 23 | 60 | 15 | 25 | 3 |
| 31 Mar 23 | 56 | 14 | 25 | 3 |
| 31 Dec 22 | 53 | 13 | 23 | 2 |
| 30 Sep 22 | 50 | 13 | 23 | 2 |
| 30 Jun 22 | 48 | 12 | 22 | 2 |
| 31 Mar 22 | 45 | 10 | 21 | 2 |
| 31 Dec 21 | 42 | 9 | 20 | 2 |
| 30 Sep 21 | 38 | 6 | 17 | 2 |
| 30 Jun 21 | 35 | 5 | 17 | 2 |
| 31 Mar 21 | 32 | 1 | 19 | 2 |
| 31 Dec 20 | 32 | 1 | 20 | 2 |
| 30 Sep 20 | 34 | 4 | 23 | 2 |
| 30 Jun 20 | 36 | 5 | 23 | 2 |
| 31 Mar 20 | 39 | 10 | 20 | 1 |
| 31 Dec 19 | 39 | 10 | 20 | 1 |
| 30 Sep 19 | 36 | 8 | 18 | 1 |
| 30 Jun 19 | 34 | 8 | 17 | 1 |
| 31 Mar 19 | 32 | 7 | 16 | 1 |
| 31 Dec 18 | 30 | 6 | 16 | 2 |
| 30 Sep 18 | 29 | 5 | 15 | 1 |
| 30 Jun 18 | 27 | 3 | 15 | 2 |
| 31 Mar 18 | 25 | 2 | 15 | 2 |
| 31 Dec 17 | 23 | 0 | 15 | 2 |
| 30 Sep 17 | 22 | 1 | 14 | 2 |
| 30 Jun 17 | 24 | 3 | 13 | 2 |
| 31 Mar 17 | 29 | 5 | 14 | 2 |
| 31 Dec 16 | 32 | 7 | 14 | 1 |
| 30 Sep 16 | 35 | 8 | 15 | 1 |
| 30 Jun 16 | 35 | 9 | 14 | 2 |
| 31 Mar 16 | 33 | 8 | 13 | 2 |
| 31 Dec 15 | 31 | 8 | 12 | 2 |
| 30 Sep 15 | 26 | 5 | 11 | 2 |
| 30 Jun 15 | 22 | 4 | 10 | 1 |
| 31 Mar 15 | 19 | 3 | 9 | 1 |
| 31 Dec 14 | 15 | 2 | 8 | 1 |
| 30 Sep 14 | 15 | 2 | 7 | 1 |
| 30 Jun 14 | 14 | 2 | 6 | 1 |
| 31 Mar 14 | 12 | 2 | 5 | 1 |
| 31 Dec 13 | 11 | 2 | 5 | 1 |
Quality Earnings: IRMD has high quality earnings.
Growing Profit Margin: IRMD's current net profit margins (26.1%) are higher than last year (25.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IRMD's earnings have grown significantly by 27.7% per year over the past 5 years.
Accelerating Growth: IRMD's earnings growth over the past year (14.1%) is below its 5-year average (27.7% per year).
Earnings vs Industry: IRMD earnings growth over the past year (14.1%) exceeded the Medical Equipment industry 12.9%.
Return on Equity
High ROE: IRMD's Return on Equity (22.3%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 11:16 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IRADIMED CORPORATION is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lawrence Solow | CJS Securities, Inc. |
| Frank Takkinen | Lake Street Capital Markets, LLC |
| Scott Henry | Roth MKM |